|Original Scoring∗||Number of Patients Receiving SAMS-CI Classification|
|Probable (9–11 Points)||Possible (7–8 Points)||Unlikely (2–6 Points)|
|Symptoms on placebo||0||1||34|
|Symptoms on both||2||8||11|
|Symptoms on neither||0||0||20|
|Revised Scoring†||Probable (9–11 Points)||Possible (5–8 Points)||Unlikely (2–4 Points)|
|Symptoms on placebo||0||3||32|
|Symptoms on both||2||12||7|
|Symptoms on neither||0||1||19|
Number of patients identified as probable, possible, and unlikely on the SAMS-CI by category of patients identified with confirmed SAMS (symptoms on statin only), symptoms on placebo, symptoms on both statin and placebo, and symptoms on neither statin or placebo from the CoEnzyme Q10 In Statin Myopathy trial (5) as well as relevant test evaluation statistics (followed by 95% confidence intervals), are shown for the original SAMS-CI scoring system and the revised scoring system based on ROC analysis).
NPV = negative predictive value; PPV = positive predictive value; ROC = receiver operating characteristics; SAMS = statin-associated muscle symptoms; SAMS-CI = Statin-Associated Muscle Symptoms Clinical Index.